CA Patent

CA3070513C — A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis

Assigned to Boehringer Ingelheim International GmbH · Expires 2023-01-03 · 3y expired

What this patent protects

The present invention relates to use of a DPP-4 inhibitor selected from linagliptin and pharmaceutically acceptable salts thereof for treating, preventing or reducing the risk of skin alterations or necrosis, associated with or induced by injections or infusions.

USPTO Abstract

The present invention relates to use of a DPP-4 inhibitor selected from linagliptin and pharmaceutically acceptable salts thereof for treating, preventing or reducing the risk of skin alterations or necrosis, associated with or induced by injections or infusions.

Drugs covered by this patent

Patent Metadata

Patent number
CA3070513C
Jurisdiction
CA
Classification
—
Expires
2023-01-03
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.